Table 1 Current Clinical Trials for siRNA Therapeutics
From: Selective gene silencing by viral delivery of short hairpin RNA
Disease | Mode of administration | Status | Company |
|---|---|---|---|
Age-related macular degeneration (AMD) | Topical | Phase II | Allergan |
Respiratory syncytial virus (RSV) | Local/direct | Phase II | Alnylam |
Liver cancer (HCC and others) | Systemic | Phase I | Alnylam |
Hepatitis B Virus (HBV) | Systemic | Phase I | Nucleonics |
Solid tumors | Systemic/local | Phase I | Calando Silence Therapeutics AG |
Acute renal failure | Systemic | Phase I | Quark Pharmaceuticals/Pfizer |
Diabetic macular edema | Topical | Phase II | Silence/Quark/Pfizer |
Metastatic melanoma | Local/direct | Phase I | Duke University |
Pachyonychia congenita | Topical | Phase Ia/b | Transderm |
High cholesterol | Systemic | Phase I | Tekmira Pharmaceuticals Corporation |
Asthma | Systemic | Phase II | ZaBeCor Pharmaceuticals |
HIV | Direct | Phase I/II | Benitec/City of Hope |